Observed Signal · Jul 30, 2026 · Funding · Source: techcrunch · Impact: 2/5 · Sentiment: Positive
Simile Raises $200M Series B at $2B Valuation
Simile, a startup that builds synthetic/simulated users for marketing and product research, raised $200 million in a Series B at a $2 billion valuation. The round, announced July 30, 2026, was led by Greenoaks with participation from Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures. The raise comes five months after Simile's $100 million Series A led by Index. Simile was founded by Joon Sung Park and counts CVS among its customers. The company positions its technology as a way to simulate user behavior for research and product testing, attracting growing VC interest in the synthetic-user market.
Significant VC investment highlights investor interest in synthetic-user technology and potential implications for market research and advertising, but it is not a major platform policy or technical change.
Track Greenoaks Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Simile closed a $200 million Series B at a $2 billion valuation (announced 2026-07-30).
- The Series B was led by Greenoaks with participation from Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures.
- The raise comes five months after Simile announced a $100 million Series A led by Index Ventures.
- Simile provides simulated/synthetic users for marketing and product research and lists CVS as a marquee customer.
- Simile was founded by Stanford PhD graduate Joon Sung Park (founder and CEO).
Connected Companies & Entities
5 Entities mapped“The B round was led by Greenoaks with participation from Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventu...”
“Just five months after emerging from stealth and announcing a $100 million Series A led by Index Ventures, it has closed a $200 million Seri...”
“The B round was led by Greenoaks with participation from Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventu...”
“The B round was led by Greenoaks with participation from Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventu...”
“Other startups in this vein have also caught VC attention, such as Aaru, which raised a Series A in December, also at a hefty 'headline' $1 ...”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Simile AI: Behavioral Simulation and Scaling Laws
This podcast episode with Simile co-founder and CEO Joon Sung Park explores the company's work building behavioral foundation models and synthetic populations for simulation. Simile has raised over $300 million at a $2 billion valuation, backed by a recent Series B. The company creates digital twins from interviews, transaction/observational data, and randomized controlled trials, enabling enterprise clients like CVS Health to test policies on simulated populations. In a 1,000-person study, digital twins reproduced human behavior about 85% as accurately as the originals. Simile has partnered with Gallup to access tens of millions of real human subjects, and aims to scale from market research and legal strategy to societal-level simulations of 'wicked problems' like climate change. The episode also discusses the company's multi-agent simulations and its long-term vision.
Isomorphic Labs seeks $5B round at $50B valuation
Isomorphic Labs, Alphabet's AI drug discovery spinout led by Demis Hassabis, is reportedly in early-stage talks to raise approximately $5 billion at a valuation of around $50 billion, according to Bloomberg. This round would follow a $2.1 billion Series B in May and a $600 million round in 2025, bringing total raised to nearly $7.7 billion within 18 months. Despite the massive funding, the company has not yet tested any drug candidate in humans; clinical trials were initially planned for end of 2025, then delayed to late 2026. Investors are valuing the platform rather than a product, a record for a pre-clinical biotech. Revenue currently comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone-based payments potentially reaching up to $2.9 billion. Skepticism remains, as Eli Lilly's CEO Dave Ricks has questioned the effectiveness of AI in drug discovery, noting that protein structure prediction is just one part of the challenge.
SiMa AI raises $150M at $1.45B valuation
SiMa.ai, a startup developing energy-efficient chips and software for edge AI applications, has raised $150 million in Series C funding, bringing its valuation to $1.45 billion. The round was co-led by Fidelity Management & Research Company and Amplify, with participation from Alter Venture Partners, Dell Technologies Capital, and StepStone Group. Founded in 2018 by Krishna Rangasayee, former COO of Groq, SiMa.ai focuses on enabling robots, drones, cameras, and other devices to run AI directly on-device, reducing reliance on cloud data exchange. The company positions its low-latency, more affordable chips as alternatives to Nvidia's GPUs. Total funding now exceeds $500 million. The startup was previously valued at $960 million after its $85 million Series B in July 2025.
Receive all future signals for Greenoaks & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.